NCT06611150 Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
| NCT ID | NCT06611150 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Sun Yat-sen University |
| Condition | Nasopharyngeal Carcinoma (NPC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2024-08-02 |
| Primary Completion | 2025-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2024-08-02 with a primary completion date of 2025-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine the maximum tolerated dose and the recommended phase II dose for nab-paclitaxel when administered concurrently with radiotherapy in nasopharyngeal carcinoma. Researchers will observe the toxicity response of patients receiving nab-paclitaxel at 180 mg/m², 200 mg/m², 230 mg/m², and 260 mg/m².
Eligibility Criteria
Inclusion Criteria: * Pathologically confirmed nasopharyngeal carcinoma * III-IVa (AJCC8th) * age 18-70 * PS score 0-1 * normal functions to tolerate chemotherapy and radiotherapy Exclusion Criteria: * The presence of other malignant neoplasms within the preceding five years, with the exception of carcinoma in situ, adequately treated non-melanoma skin cancer and papillary thyroid cancer, is permitted. * Symptomatic heart failure, unstable angina, myocardial infarction, active infections requiring systemic therapy, psychiatric disorders, or family and social factors
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06611150 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Nasopharyngeal Carcinoma (NPC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06611150 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06611150 currently recruiting?
Yes, NCT06611150 is actively recruiting participants. Contact the research team at xiefy@sysucc.org.cn for enrollment information.
Where is the NCT06611150 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06611150 clinical trial?
NCT06611150 is sponsored by Sun Yat-sen University. The trial plans to enroll 24 participants.